GLADYS BLACKBURN: Open Payments
NPI 1861005589 · PERU, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$562 in 38 payments from 12 companies in 2025. Trend: 2023 $502 · 2024 $119 · 2025 $562
Food & beverage: $562
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $189 |
| AstraZeneca Pharmaceuticals LP | 4 | $72 |
| Novo Nordisk Inc | 4 | $72 |
| Exact Sciences Corporation | 3 | $49 |
| Astellas Pharma US Inc | 2 | $47 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Dexcom, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
Products named: VRAYLAR, Ozempic, Cologuard Collection Kit, Veozah, QULIPTA, VOQUEZNA, Dexcom G6 Transmitter, AIRSUPRA.
Industry payments across IN — which companies pay providers there.
